DALLAS and TORONTO, Oct. 11,
2023 /CNW/ - Perimeter Medical Imaging AI, Inc.
(TSXV: PINK) (OTC: PYNKF) (FSE: 4PC) ("Perimeter" or the
"Company") – a commercial-stage medical technology company –
announced that patient randomization is underway at Mayo Clinic in
Florida, the most recent clinical
site to be initiated as part of an ongoing multi-center, randomized
two-arm pivotal clinical trial evaluating the investigational
Perimeter B-Series OCT combined with its proprietary ImgAssist AI
software.
Dr. Sarah Butler, Perimeter's
Vice President, Clinical and Medical Affairs stated, "Patient
recruitment and randomization is underway at the Mayo Clinic in
Florida, which is one of the sites
where we are studying the combination of the Perimeter B-Series
medical imaging platform with artificial intelligence software.
Combining high-resolution optical coherence tomography with AI
algorithms can potentially help surgeons better identify regions of
interest during breast conserving surgeries, with the aim of
improving patient outcomes and reducing healthcare costs."
Adrian Mendes, Perimeter's Chief
Executive Officer stated, "We are pleased that we continue to
advance our ongoing pivotal clinical trial, supporting our goal to
expedite the development of our next-gen AI technology. With its
potential to become the new standard for specimen imaging
technology during breast conservation surgery, our hope is that the
data generated from this study will support the commercialization
of Perimeter B-Series."
About Perimeter Medical Imaging
AI, Inc.
Based in Toronto, Canada and
Dallas, Texas, Perimeter Medical
Imaging AI (TSX-V: PINK) (OTC: PYNKF) (FSE: 4PC) is
a medical technology company driven to transform cancer surgery
with ultra-high-resolution, real-time, advanced imaging tools to
address areas of high unmet medical need. Available across the
U.S., our FDA-cleared Perimeter S-Series OCT system provides
real-time, cross-sectional visualization of excised tissues at the
cellular level. The breakthrough-device-designated investigational
Perimeter B-Series OCT with ImgAssist AI represents our
next-generation artificial intelligence technology that is
currently being evaluated in a pivotal clinical trial, with support
from a grant of up to US$7.4 million
awarded by the Cancer Prevention and Research Institute of
Texas. The company's ticker symbol
"PINK" is a reference to the pink ribbons used during Breast Cancer
Awareness Month.
Neither the TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in policies of the TSX Venture
Exchange) accepts responsibility for the adequacy or accuracy of
this release.
Forward-Looking
Statements
This news release contains statements that constitute
"forward-looking information" within the meaning of applicable
Canadian securities legislation. In this news release, words such
as "may," "would," "could," "will," "likely," "believe," "expect,"
"anticipate," "intend," "plan," "estimate," and similar words and
the negative form thereof are used to identify forward-looking
statements. Forward-looking information may relate to management's
future outlook and anticipated events or results and may include
statements or information regarding the future financial position,
business strategy and strategic goals, competitive conditions,
research and development activities, projected costs and capital
expenditures, research and clinical testing outcomes, taxes and
plans and objectives of, or involving, Perimeter. Without
limitation, information regarding the potential benefits of
Perimeter S-Series OCT, Perimeter B-Series OCT, and Perimeter
ImgAssist; details regarding Perimeter's ongoing clinical trials;
and the anticipated completion date of Perimeter's clinical trials,
are forward-looking information. Forward-looking statements should
not be read as guarantees of future performance or results, and
will not necessarily be accurate indications of whether, or the
times at or by which, any particular result will be achieved. No
assurance can be given that any events anticipated by the
forward-looking information will transpire or occur.
Forward-looking information is based on information available at
the time and/or management's good-faith belief with respect to
future events and are subject to known or unknown risks,
uncertainties, assumptions, and other unpredictable factors, many
of which are beyond Perimeter's control. Such forward-looking
statements reflect Perimeter's current view with respect to future
events, but are inherently subject to significant medical,
scientific, business, economic, competitive, political, and social
uncertainties and contingencies. In making forward-looking
statements, Perimeter may make various material assumptions,
including but not limited to (i) the accuracy of Perimeter's
financial projections; (ii) obtaining positive results from trials;
(iii) obtaining necessary regulatory approvals; and (iv) general
business, market, and economic conditions. Further risks,
uncertainties and assumptions include, but are not limited to,
those applicable to Perimeter and described in Perimeter's
Management Discussion and Analysis for the year ended December 31, 2022, which is available on
Perimeter's SEDAR profile at www.sedar.com, and could cause actual
events or results to differ materially from those projected in any
forward-looking statements. Perimeter does not intend, nor does
Perimeter undertake any obligation, to update or revise any
forward-looking information contained in this news release to
reflect subsequent information, events, or circumstances or
otherwise, except if required by applicable laws.
View original
content:https://www.prnewswire.com/news-releases/perimeter-medical-imaging-ai-announces-patient-randomization-underway-at-clinical-trial-site-at-mayo-clinic-in-florida-301953098.html
SOURCE Perimeter Medical Imaging, Inc.